Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19224687 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | May 2025 | January 2026 | Allow | 7 | 0 | 1 | No | No |
| 19050632 | TREATMENT FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION WITH GUANETHIDINE AND GUANADREL | February 2025 | February 2026 | Abandon | 12 | 1 | 0 | No | No |
| 18875945 | TRYPTAMINE DERIVATIVES | December 2024 | January 2026 | Abandon | 13 | 1 | 0 | No | No |
| 18967341 | WOUND TREATMENTS AND COMPOSITIONS | December 2024 | September 2025 | Allow | 9 | 1 | 0 | No | No |
| 18951543 | PLEUROMUTILIN DERIVATIVE CONTAINING A THIAZOLO[5,4-C]PYRIDINE SIDE CHAIN, AND A PREPARATION METHOD AND APPLICATION THEREOF | November 2024 | March 2025 | Allow | 4 | 0 | 1 | No | No |
| 18927412 | STABLE FORMS OF CAPSAICIN PALMITATE FOR THE TREATMENT OF PAIN | October 2024 | July 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18855893 | TRYPTAMINE DERIVATIVES | October 2024 | March 2026 | Allow | 17 | 2 | 0 | No | No |
| 18843258 | COMPOUND WITH BROAD-SPECTRUM ANTIBACTERIAL ACTIVITY AND ITS ANTIBACTERIAL COMPOSITION | September 2024 | July 2025 | Allow | 10 | 1 | 0 | No | No |
| 18811608 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | August 2024 | July 2025 | Abandon | 11 | 1 | 1 | No | No |
| 18778305 | TREATMENT OF PAIN AND VASOCONSTRICTION | July 2024 | March 2026 | Abandon | 20 | 3 | 0 | No | No |
| 18729953 | SHORT-ACTING MONOAMINE RELEASERS | July 2024 | December 2025 | Allow | 17 | 1 | 1 | No | No |
| 18644865 | KINASE INHIBITORS AND RELATED METHODS OF USE | April 2024 | January 2026 | Abandon | 21 | 1 | 0 | No | No |
| 18703647 | BORATE COMPLEXES OF CHLOROGENIC ACID AND USES THEREOF | April 2024 | January 2026 | Allow | 21 | 3 | 1 | Yes | No |
| 18700875 | CRYSTALLINE TRYPTAMINE COMPOUNDS | April 2024 | August 2025 | Allow | 16 | 2 | 0 | No | No |
| 18631891 | COMBINATION THERAPY FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMORS | April 2024 | January 2026 | Allow | 21 | 2 | 0 | No | No |
| 18695071 | SUBSTITUTED ALPHA-ETHYL PHENYLALKYLAMINES | March 2024 | September 2025 | Allow | 18 | 1 | 1 | Yes | No |
| 18609892 | Compositions and Methods for Increasing Athletic Performance | March 2024 | October 2025 | Allow | 19 | 1 | 0 | No | No |
| 18606346 | RET INHIBITOR FOR USE IN TREATING CANCER HAVING A RET ALTERATION | March 2024 | September 2025 | Allow | 18 | 1 | 0 | No | No |
| 18600632 | METHODS AND COMPOSITIONS FOR SOFT ANTICHOLINERGIC ESTERS | March 2024 | July 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18429785 | System and method for non-surgical treatment of prolapsed hemorrhoids | February 2024 | March 2025 | Allow | 13 | 1 | 3 | Yes | No |
| 18418122 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | January 2024 | January 2026 | Allow | 24 | 2 | 0 | No | No |
| 18406732 | METHODS OF TREATING CONDITIONS RELATED TO THE S1P1 RECEPTOR | January 2024 | March 2025 | Allow | 14 | 1 | 0 | No | No |
| 18394435 | KETAMINE OR DEXTROMETHORPHAN FORMULATIONS AND METHODS OF USE | December 2023 | February 2026 | Abandon | 26 | 2 | 0 | No | No |
| 18382307 | TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS | October 2023 | January 2025 | Allow | 15 | 2 | 1 | Yes | No |
| 18472660 | Apixaban Dosing | September 2023 | January 2025 | Allow | 16 | 1 | 3 | Yes | No |
| 18355811 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | July 2023 | December 2025 | Allow | 29 | 1 | 1 | No | No |
| 18219057 | ENTACTOGEN-ASSISTED THERAPY FOR ALCOHOL USE DISORDER AND ADDICTION-RELATED CONDITIONS AND COMORBIDITIES | July 2023 | November 2025 | Abandon | 28 | 2 | 1 | No | No |
| 18324359 | METHODS FOR TREATING VIRAL DISORDERS | May 2023 | June 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18315285 | INHIBITION OF OLIG2 ACTIVITY | May 2023 | June 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18133176 | METHODS OF TREATING SUICIDALITY | April 2023 | June 2025 | Allow | 26 | 4 | 0 | No | No |
| 18125800 | METHOD OF PREPARING LOXAPINE FILM ORAL DOSAGE FORM | March 2023 | June 2025 | Abandon | 27 | 3 | 0 | No | No |
| 18005838 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH HERPES SIMPLEX VIRUS | January 2023 | March 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18154700 | Methods of Treating or Preventing Acute Respiratory Distress Syndrome | January 2023 | January 2026 | Abandon | 36 | 3 | 0 | No | No |
| 18015381 | TRIAZINE COMPOUND AND COMPOSITION AND USE THEREOF | January 2023 | October 2025 | Allow | 33 | 1 | 1 | No | No |
| 17989673 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | November 2022 | February 2026 | Abandon | 39 | 1 | 1 | No | No |
| 17777769 | USE OF FAK INHIBITOR IN PREPARATION OF DRUG FOR TREATING TUMORS HAVING NRAS MUTATION | November 2022 | February 2026 | Abandon | 45 | 2 | 1 | No | No |
| 18046513 | APPLICATION OF THYROID HORMONES AND THYROID HORMONE ANALOGUES TO PREPARATION OF DRUGS FOR TREATING SICKLE-CELL DISEASE | October 2022 | January 2026 | Allow | 39 | 2 | 0 | Yes | No |
| 17904934 | CANNABINOID COMPOSITIONS | August 2022 | March 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17807184 | TREATMENT OF MODERATE TO SEVERE INFLUENZA | June 2022 | January 2026 | Abandon | 43 | 1 | 0 | No | No |
| 17734102 | MOVEMENT DISORDERS | May 2022 | January 2026 | Allow | 44 | 5 | 0 | Yes | No |
| 17755022 | COMPOSITIONS COMPRISING A DHODH INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA | April 2022 | January 2026 | Abandon | 45 | 0 | 1 | No | No |
| 17597729 | 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | January 2022 | January 2026 | Allow | 48 | 1 | 1 | Yes | No |
| 17529791 | FULVESTRANT FORMULATIONS | November 2021 | March 2025 | Allow | 40 | 4 | 0 | Yes | No |
| 17529609 | CANCER TREATMENT MODALITIES | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17334872 | MRGPRX2 ANTAGONIST FOR THE TREATMENT OF PSEUDO ALLERGIC REACTIONS | May 2021 | March 2026 | Allow | 57 | 4 | 1 | No | No |
| 17325937 | METHODS OF TREATING CANCERS | May 2021 | April 2025 | Allow | 47 | 3 | 2 | No | No |
| 17228025 | QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION | April 2021 | November 2025 | Allow | 55 | 4 | 1 | Yes | Yes |
| 17280075 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | March 2021 | January 2026 | Allow | 58 | 2 | 1 | Yes | No |
| 17257458 | Oral Pharmaceutical Formulations of Bitter Compounds for Pulmonary Hypertension | December 2020 | November 2024 | Allow | 46 | 2 | 1 | No | No |
| 17059297 | NUPR1 INHIBITION FOR TREATING CANCER | November 2020 | September 2024 | Abandon | 45 | 2 | 1 | No | No |
| 17057199 | FUSED-CYCLIC PYRAZOLONE FORMAMIDE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | November 2020 | July 2025 | Allow | 56 | 2 | 1 | No | No |
| 17040893 | ORGANIC COMPOUNDS | September 2020 | March 2026 | Allow | 60 | 5 | 1 | No | No |
| 16483366 | METHODS OF PROTECTING AGAINST NEURODEGENERATION | August 2019 | November 2025 | Allow | 60 | 8 | 2 | Yes | No |
| 16343681 | DUAL INHIBITORS OF VISTA AND PD-1 PATHWAYS | April 2019 | April 2025 | Abandon | 60 | 7 | 1 | No | Yes |
| 16342730 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | April 2019 | June 2025 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16381975 | WOUND TREATMENTS AND COMPOSITIONS | April 2019 | August 2025 | Allow | 60 | 5 | 2 | No | Yes |
| 15561390 | P38 MAP KINASE INHIBITORS FOR TREATING FRIEDREICH’S ATAXIA | September 2017 | March 2025 | Allow | 60 | 7 | 1 | Yes | Yes |
| 14858029 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | September 2015 | June 2017 | Allow | 24 | 1 | 1 | No | No |
| 14233228 | Histone Deacetylase 6 Selective Inhibitors for the Treatment of Bone Disease | April 2014 | July 2016 | Allow | 30 | 2 | 1 | No | No |
| 14351360 | BIOCIDAL COMPOSITIONS AND METHODS OF USE | April 2014 | August 2016 | Allow | 28 | 2 | 1 | No | No |
| 14234916 | NOVEL ESTROGEN RECEPTOR LIGANDS | April 2014 | October 2016 | Allow | 33 | 2 | 1 | No | No |
| 14189543 | COMPOSITION FOR ELIMINATION OF TROUBLESOME VARMINTS | February 2014 | November 2016 | Allow | 33 | 3 | 0 | No | No |
| 14131849 | C-3 SUBSTITUTED BICYCLOOCTANE BASED HIV PROTEASE INHIBITORS | January 2014 | December 2015 | Allow | 23 | 1 | 1 | No | No |
| 14005462 | DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF | December 2013 | March 2016 | Allow | 30 | 2 | 1 | Yes | No |
| 14009969 | SMALL MOLECULES FOR TREATING BREAST CANCER | November 2013 | February 2016 | Allow | 28 | 2 | 1 | No | No |
| 14053736 | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORgammat | October 2013 | October 2015 | Allow | 24 | 1 | 1 | No | No |
| 13884900 | Cyanoenamines and their use as fungicides | July 2013 | June 2016 | Allow | 37 | 3 | 1 | No | No |
| 13930765 | PHARMACEUTICAL FORMULATION FOR REDUCING FREQUENCY OF URINATION AND METHOD OF USE THEREOF | June 2013 | June 2016 | Allow | 36 | 5 | 1 | Yes | No |
| 13994048 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS | June 2013 | June 2015 | Allow | 24 | 2 | 1 | Yes | No |
| 13883038 | Antimalarial Drug Comprising Alaremycin or Derivative Thereof as Active Ingredient | May 2013 | December 2015 | Allow | 31 | 1 | 1 | No | No |
| 13843391 | Chlorhexadine Antiseptic | March 2013 | April 2014 | Allow | 13 | 2 | 0 | Yes | No |
| 13829062 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | March 2013 | July 2015 | Allow | 28 | 2 | 1 | Yes | No |
| 13814148 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | March 2013 | December 2016 | Allow | 46 | 5 | 0 | Yes | No |
| 13643960 | PESTICIDAL COMPOSITION AND ITS USE | November 2012 | February 2016 | Allow | 39 | 4 | 1 | No | No |
| 13558491 | Method of Lowering Serum Uric Acid Levels With (S)-Tofisopam | July 2012 | March 2016 | Allow | 44 | 2 | 1 | Yes | No |
| 13393436 | PHTHALANILATE COMPOUNDS AND METHODS OF USE | May 2012 | May 2014 | Allow | 27 | 0 | 2 | No | No |
| 13467764 | Inhibitors of PFKFB3 for Cancer Therapy | May 2012 | June 2016 | Allow | 49 | 4 | 1 | Yes | No |
| 13386199 | FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES | April 2012 | May 2015 | Allow | 39 | 3 | 1 | Yes | No |
| 13389504 | PYRIMIDONE COMPOUNDS | April 2012 | September 2014 | Allow | 31 | 2 | 1 | No | No |
| 13440113 | (1,2,3-Triazolyl)sulfonyl Derivatives | April 2012 | March 2014 | Allow | 24 | 1 | 1 | Yes | No |
| 13381583 | L-SERINE TO BE USED AS A DRUG FOR PREVENTING AND/OR TREATING AN INFLAMMATORY RESPONSE OF THE SKIN | March 2012 | May 2018 | Allow | 60 | 9 | 1 | Yes | Yes |
| 13390657 | SUBSTITUTED HYDRAZIDE COMPOUNDS AND USE THEREOF | February 2012 | October 2015 | Allow | 44 | 4 | 0 | Yes | Yes |
| 13368468 | AROMATIC AND AROMATIC/HETEROAROMATIC MOLECULAR STRUCTURES WITH CONTROLLABLE ELECTRON CONDUCTING PROPERTIES | February 2012 | September 2014 | Allow | 31 | 2 | 1 | Yes | No |
| 13360066 | HETEROCYCLIC COMPOUND | January 2012 | February 2015 | Allow | 36 | 3 | 1 | No | No |
| 13176851 | COMPOSITIONS DERIVED FROM METATHESIZED NATURAL OILS AND AMINES AND METHODS OF MAKING | July 2011 | December 2015 | Allow | 53 | 3 | 2 | No | No |
| 13111993 | ORALLY DISINTEGRATING TABLETS OF ZOLMITRIPTAN AND PROCESS FOR PREPARING THE SAME | May 2011 | September 2014 | Allow | 40 | 3 | 1 | No | No |
| 12357816 | METHODS FOR PREVENTING AND TREATING THROMBOTIC DISORDERS | January 2009 | August 2014 | Allow | 60 | 5 | 1 | Yes | No |
| 11885946 | Antipruritic Agent for Pruritus Caused by Multiple Sclerosis | May 2008 | February 2015 | Allow | 60 | 6 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEE, ANDREW P.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 22.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LEE, ANDREW P works in Art Unit 1691 and has examined 46 patent applications in our dataset. With an allowance rate of 93.5%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner LEE, ANDREW P's allowance rate of 93.5% places them in the 81% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by LEE, ANDREW P receive 3.17 office actions before reaching final disposition. This places the examiner in the 90% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by LEE, ANDREW P is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +12.0% benefit to allowance rate for applications examined by LEE, ANDREW P. This interview benefit is in the 47% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 25.4% of applications are subsequently allowed. This success rate is in the 40% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 47.1% of cases where such amendments are filed. This entry rate is in the 71% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 2% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 66.7% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 33.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 54.5% are granted (fully or in part). This grant rate is in the 55% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.3% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.